S&P 500   3,602.58 (-0.98%)
DOW   29,507.83 (-1.35%)
QQQ   297.17 (-0.62%)
AAPL   118.01 (+1.22%)
MSFT   211.57 (-1.70%)
FB   273.33 (-1.61%)
GOOGL   1,756.83 (-1.69%)
AMZN   3,153.43 (-1.31%)
TSLA   579.38 (-1.09%)
NVDA   525.12 (-1.00%)
BABA   265.31 (-4.04%)
CGC   28.41 (-2.03%)
GE   10.26 (-1.35%)
MU   64.18 (-0.08%)
AMD   88.37 (+1.35%)
T   28.92 (-0.38%)
NIO   51.32 (-4.96%)
F   9.12 (+0.33%)
ACB   10.72 (+2.39%)
NFLX   484.92 (-1.31%)
BA   212.23 (-1.97%)
GILD   59.81 (-0.37%)
DIS   147.52 (+0.27%)
S&P 500   3,602.58 (-0.98%)
DOW   29,507.83 (-1.35%)
QQQ   297.17 (-0.62%)
AAPL   118.01 (+1.22%)
MSFT   211.57 (-1.70%)
FB   273.33 (-1.61%)
GOOGL   1,756.83 (-1.69%)
AMZN   3,153.43 (-1.31%)
TSLA   579.38 (-1.09%)
NVDA   525.12 (-1.00%)
BABA   265.31 (-4.04%)
CGC   28.41 (-2.03%)
GE   10.26 (-1.35%)
MU   64.18 (-0.08%)
AMD   88.37 (+1.35%)
T   28.92 (-0.38%)
NIO   51.32 (-4.96%)
F   9.12 (+0.33%)
ACB   10.72 (+2.39%)
NFLX   484.92 (-1.31%)
BA   212.23 (-1.97%)
GILD   59.81 (-0.37%)
DIS   147.52 (+0.27%)
S&P 500   3,602.58 (-0.98%)
DOW   29,507.83 (-1.35%)
QQQ   297.17 (-0.62%)
AAPL   118.01 (+1.22%)
MSFT   211.57 (-1.70%)
FB   273.33 (-1.61%)
GOOGL   1,756.83 (-1.69%)
AMZN   3,153.43 (-1.31%)
TSLA   579.38 (-1.09%)
NVDA   525.12 (-1.00%)
BABA   265.31 (-4.04%)
CGC   28.41 (-2.03%)
GE   10.26 (-1.35%)
MU   64.18 (-0.08%)
AMD   88.37 (+1.35%)
T   28.92 (-0.38%)
NIO   51.32 (-4.96%)
F   9.12 (+0.33%)
ACB   10.72 (+2.39%)
NFLX   484.92 (-1.31%)
BA   212.23 (-1.97%)
GILD   59.81 (-0.37%)
DIS   147.52 (+0.27%)
S&P 500   3,602.58 (-0.98%)
DOW   29,507.83 (-1.35%)
QQQ   297.17 (-0.62%)
AAPL   118.01 (+1.22%)
MSFT   211.57 (-1.70%)
FB   273.33 (-1.61%)
GOOGL   1,756.83 (-1.69%)
AMZN   3,153.43 (-1.31%)
TSLA   579.38 (-1.09%)
NVDA   525.12 (-1.00%)
BABA   265.31 (-4.04%)
CGC   28.41 (-2.03%)
GE   10.26 (-1.35%)
MU   64.18 (-0.08%)
AMD   88.37 (+1.35%)
T   28.92 (-0.38%)
NIO   51.32 (-4.96%)
F   9.12 (+0.33%)
ACB   10.72 (+2.39%)
NFLX   484.92 (-1.31%)
BA   212.23 (-1.97%)
GILD   59.81 (-0.37%)
DIS   147.52 (+0.27%)
Log in
NASDAQ:DARE

Daré Bioscience Stock Forecast, Price & News

$1.36
+0.01 (+0.37 %)
(As of 11/30/2020 10:18 AM ET)
Add
Compare
Today's Range
$1.35
Now: $1.36
$1.38
50-Day Range
$0.96
MA: $1.08
$1.33
52-Week Range
$0.75
Now: $1.36
$2.22
Volume7,568 shs
Average Volume954,456 shs
Market Capitalization$51.48 million
P/E RatioN/A
Dividend YieldN/A
Beta1.94
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application; Ovaprene, a non-hormonal monthly contraceptive vaginal ring; and Sildenafil Cream, a cream formulation of sildenafil to treat female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone replacement therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone- receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and for fertility support in an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-RH1, a non-hormonal contraception for men and women; ORB-204 and ORB-214 that are formulations of injectable etonogestrel for contraception; and a microchip-based implantable drug delivery system to provide contraception. The company has license agreement with ADVA-Tec, Inc. to develop and commercialize Ovaprene for human contraceptive use; and license and collaboration agreement with Strategic Science & Technologies-D, LLC and Strategic Science & Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. Daré Bioscience, Inc. is headquartered in San Diego, California.
Read More
Daré Bioscience logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DARE
CUSIPN/A
Phone858-926-7655
Employees15

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.04) per share

Profitability

Net Income$-14,260,000.00

Miscellaneous

Market Cap$51.48 million
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable
$1.36
+0.01 (+0.37 %)
(As of 11/30/2020 10:18 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Daré Bioscience (NASDAQ:DARE) Frequently Asked Questions

How has Daré Bioscience's stock been impacted by Coronavirus (COVID-19)?

Daré Bioscience's stock was trading at $1.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DARE stock has increased by 34.2% and is now trading at $1.3550.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Daré Bioscience?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Daré Bioscience
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Daré Bioscience?

Wall Street analysts have given Daré Bioscience a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Daré Bioscience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Daré Bioscience's next earnings date?

Daré Bioscience is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Daré Bioscience
.

How were Daré Bioscience's earnings last quarter?

Daré Bioscience, Inc. (NASDAQ:DARE) released its quarterly earnings results on Tuesday, November, 17th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.07.
View Daré Bioscience's earnings history
.

What price target have analysts set for DARE?

5 brokerages have issued 1-year price objectives for Daré Bioscience's stock. Their forecasts range from $3.00 to $7.50. On average, they anticipate Daré Bioscience's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 232.1% from the stock's current price.
View analysts' price targets for Daré Bioscience
.

Are investors shorting Daré Bioscience?

Daré Bioscience saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 250,400 shares, an increase of 296.8% from the October 15th total of 63,100 shares. Based on an average daily volume of 508,000 shares, the short-interest ratio is currently 0.5 days.
View Daré Bioscience's Short Interest
.

Who are some of Daré Bioscience's key competitors?

What other stocks do shareholders of Daré Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

Who are Daré Bioscience's key executives?

Daré Bioscience's management team includes the following people:
  • Ms. Sabrina Martucci Johnson, Pres, CEO & Director (Age 53, Pay $488.22k)
  • Ms. Lisa Walters-Hoffert, CFO & Sec. (Age 61, Pay $358.67k)
  • Mr. Mark Walters, VP of Operations (Age 65)
  • Ms. MarDee J. Haring-Layton, VP of Accounting & Fin. (Age 44)
  • Dr. David Friend, Chief Scientific Officer
  • Mr. John A. Fair, Chief Strategy Officer (Age 48)
  • Ms. Mary Jarosz, Global Head of Regulatory Affairs
  • Mr. John Katsilometes, Controller

What is Daré Bioscience's stock symbol?

Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE."

How do I buy shares of Daré Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Daré Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $1.36.

How big of a company is Daré Bioscience?

Daré Bioscience has a market capitalization of $51.48 million. The biotechnology company earns $-14,260,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Daré Bioscience employs 15 workers across the globe.

What is Daré Bioscience's official website?

The official website for Daré Bioscience is www.darebioscience.com.

How can I contact Daré Bioscience?

Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.